ANGPTL3 deficiency is traditionally associated with reduced cardiovascular risk and serum lipid concentrations; as a consequence, the inhibition of ANGPTL3 by evinacumab may be a new therapeutic option for the management of dyslipidaemia [99]. Here, ANGPTL3 is linked to inherited lipid metabolism disorder.